Gadodiamide
| Storage | Store at -20°C |
| M.Wt | 591.67 |
| Cas No. | 122795-43-1 |
| Formula | C16H28GdN5O9 |
| Solubility | ≥29.2 mg/mL in H2O; insoluble in EtOH; ≥8.3 mg/mL in DMSO |
| Chemical Name | 2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate;gadolinium(3+);hydrate |
| SDF | Download SDF |
| Canonical SMILES | CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].O.[Gd+3] |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Animal experiment [1]: | |
|
Animal models |
Rats or monkeys |
|
Dosage form |
0.25 ~ 10 mmol/kg; i.v |
|
Applications |
In rats, a single dose of Gadodiamide at a greater than 0.5 mmol/kg induced vacuolization of the proximal tubular cells in kidneys, without affecting renal function. At a dose up to 10 mmol/kg, the vacuolization was only at the moderate degree, and was shown to regress partially during the 7 days after administration. In monkeys, administration of 0.25 mmol/kg Gadodiamide (q.d.; for 28 days) exhibited no effect on the kidneys. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol. 1993 Mar;28 Suppl 1:S28-43. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
